PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease. Lu C, Yan HH, Zhang CY, Chen SY, et al. Clin Lung Cancer 2025;26:263-266.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lu C, Yan HH, Zhang CY, Chen SY, et al. PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System Disease. Clin Lung Cancer 2025;26:263-266.
PMID: 39721825